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Histone deacetylase inhibitors (HDACi) are being investigated for the control of various human parasites.
Here we investigate their potential as insecticides for the control of a major ecto-parasite of sheep, the
Australian sheep blowﬂy, Lucilia cuprina. We assessed the ability of HDACi from various chemical classes
to inhibit the development of blowﬂy larvae in vitro, and to inhibit HDAC activity in nuclear protein
extracts prepared from blowﬂy eggs. The HDACi prodrug romidepsin, a cyclic depsipeptide that forms a
thiolate, was the most potent inhibitor of larval growth, with equivalent or greater potency than three
commercial blowﬂy insecticides. Other HDACi with potent activity were hydroxamic acids (trichostatin,
CUDC-907, AR-42), a thioester (KD5170), a disulphide (Psammaplin A), and a cyclic tetrapeptide bearing a
ketone (apicidin). On the other hand, no insecticidal activity was observed for certain other hydroxamic
acids, fatty acids, and the sesquiterpene lactone parthenolide. The structural diversity of the 31
hydroxamic acids examined here revealed some structural requirements for insecticidal activity; for
example, among compounds with ﬂexible linear zinc-binding extensions, greater potency was observed
in the presence of branched capping groups that likely make multiple interactions with the blowﬂy
HDAC enzymes. The insecticidal activity correlated with inhibition of HDAC activity in blowﬂy nuclear
protein extracts, indicating that the toxicity was most likely due to inhibition of HDAC enzymes in the
blowﬂy larvae. The inhibitor potencies against blowﬂy larvae are different from inhibition of human
HDACs, suggesting some selectivity for human over blowﬂy HDACs, and a potential for developing
compounds with the inverse selectivity. In summary, these novel ﬁndings support blowﬂy HDAC en-
zymes as new targets for blowﬂy control, and point to development of HDAC inhibitors as a promising
new class of insecticides.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Australian sheep blowﬂy (Lucilia cuprina) is an important
ecto-parasite that causes ﬂy strike, which has signiﬁcant health and
welfare, as well as economic, impacts on the sheep industry in
Australia (Sandeman et al., 2014). The female blowﬂy is attracted to
the sheep by odours, particularly those associated with bacterial
infections in damp ﬂeece, and lays eggs (Tellam and Bowles, 1997).
The developing larvae feed on the sheep, causing severe tissue, 306 Carmody Rd., St. Lucia,
).
Ltd on behalf of Australian Society fdamage, toxaemia, and in some cases, death. The consequent loss of
livestock, costs of preventative and curative chemical treatments,
and animal welfare issues place signiﬁcant economic burdens on
livestock enterprises (Lane et al., 2015). The blowﬂy has developed
resistance to various classes of chemical insecticides used for its
control, including organochlorines, organophosphates, the
benzoyl-phenyl urea diﬂubenzuron (Levot, 1995; Sandeman et al.,
2014) as well as the triazine cyromazine (Levot, 2012). Only two
preventative blowﬂy control chemicals, the macrocyclic lactone
ivermectin and the cyanopyrimidine dicyclanil, remain effective
with no resistance yet reported. There is therefore a need to iden-
tify new chemical classes of insecticides, preferably with different
target proteins, to control this important parasitic insect.
Histone deacetylase inhibitors (HDACi) have been recognised as
therapeutic targets in cancer for many years (Cairns, 2001), with aor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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have also been studied extensively over recent years for their po-
tential in chemotherapy for parasitic diseases of humans, including
malaria, toxoplasmosis, trypanosomiasis, schistosomiasis and
leishamaniasis (Andrews et al., 2012a,b; Marek et al., 2015). HDAC
enzymes have been studied extensively in the model dipteran in-
sect Drosophilawith respect to their roles in longevity and memory
formation (Fitzsimons et al., 2013; Proshkina et al., 2015; Schwartz
et al., 2016), with a Drosophila model providing experimental evi-
dence to highlight HDACi as potential therapeutics for the treat-
ment of Huntington's disease (Sharma and Taliyan, 2015). However,
only a single study has reported the insecticidal activity of an HDACi
against this ﬂy species, with Pile et al. (2001) noting that trichos-
tatin caused lethality during larval development. The potential for
HDACi as insecticides was recently highlighted by Kotze et al.
(2015) who showed that trichostatin and suberoylanilide
hydroxamic acid (SAHA) were able to inhibit the development of
sheep blowﬂy larvae in vitro. That report also highlighted similar-
ities and differences in amino acid sequences of blowﬂy and human
HDAC enzymes, with differences particularly noted between spe-
cies for the Class II enzymes HDAC4 and 6, and the Class IV HDAC11,
raising the possibility of identifying insect-speciﬁc inhibitors.
The present study expands on our earlier report of insecticidal
activity for trichostatin and SAHA (Kotze et al., 2015) by examining
other HDACi with different chemical structures and mechanisms of
action. We focus on hydroxamic acids since these are the best
known group of HDACi, but also include inhibitors with different
chemical components, such as benzamides, thioesters, thiolates,
disuﬁdes, cyclic depsi- and tetra-peptides, fatty acids, and sesqui-
terpene lactones (Table 1). We measure the effects of these HDACi
on the development of blowﬂy larvae (larval growth rate and pu-
pation rate) and on the HDAC enzyme activity of nuclear protein
extracts prepared from blowﬂy eggs. We also compare these results
with reported inhibitory activities against human HDAC enzymes
as an initial step towards identiﬁcation of insect-speciﬁc inhibitors.
2. Materials and methods
2.1. Insects and chemicals
The L. cuprina used in this study were from the laboratory
reference drug-susceptible LS strain, derived from collections made
in the Australian Capital Territory (Canberra, Australia) over 40
years ago. This strain has beenmaintained in a laboratory since that
time (in Canberra for 30 years, and then at CSIRO and University of
Queensland laboratories in Brisbane for the last 10 years), and has
no history of exposure to insecticides. Adult ﬂies were maintained
at 28 C and 80% relative humidity with a daily photoperiod of light
16 h and dark 8 h. Adults were fed a diet of sugar and water, while
larvae were raised on awheatgerm culture medium (Tachibana and
Numata, 2001). Protein meals (bovine liver) were provided on days
4 and 8 after adult eclosion in order to prime adult ﬂies for sub-
sequent egg-laying. For provision of eggs for bioassays, liver was
placed into cages of gravid ﬂies for a period of two hours (12 p.m.
until 2 p.m.). The liver was then removed and kept at room tem-
perature overnight. At 10 a.m. the next morning, assays were
established using the newly-hatched larvae.
HDACi were synthesized by reported procedures or obtained
from commercial sources (Table 1). The structures are shown in
Supplementary Figs. 1e4. Stock solutions for use in larval bioassays
were prepared in ethanol at a concentration of 1 mg/mL. In cases
where the compound did not dissolve at this concentration the
solutions were further diluted 2-fold with ethanol until no pre-
cipitate was evident (to give stocks at 0.5 or 0.25 mg/mL). Excep-
tions were CUDC-907 and MC1568 which required dilution to aconcentration of 0.05 mg/mL. The commercial insecticide stocks
used as controls were prepared at 1 mg/mL in water (cyromazine
and dicyclanil) or acetone (diﬂubenzuron). Stock solutions of HDACi
for use in nuclear extract HDAC enzyme assays were prepared at
1 mg/mL in DMSO.
2.2. Blowﬂy larval bioassay
The effects of HDACi on the growth of blowﬂy larvae was
assessed using a bioassay system in which larvae were allowed to
develop on cotton wool impregnated with the compounds at
various concentrations (modiﬁed slightly from Kotze et al., 2014).
Brieﬂy, 4 mL aliquots of HDACi or commercial insecticide solutions
were added to cotton wool plugs and the solvent (4 mL of either
ethanol, acetone, or water) was allowed to evaporate overnight.
Control containers were prepared by addition of 4 mL of the rele-
vant solvent to the cottonwool. The next day (Day 0 of the assay), a
sheep serum-based medium (80 g/L yeast extract (Merck), 1.6 mg/
mL tylosin (Sigma) in lamb serum (Life Technologies) buffered with
35mMKH2PO4, pH7.5) was added to the cottonwool, and groups of
50 freshly-hatched larvae (prepared as described in section 2.1,
above) were placed onto the cotton wool. The assay pots were
placed at 28 C. In order to calculate mean larval weight at the
beginning of the drug exposure period, two groups of 100 larvae
were collected, blotted dry on paper towel, weighed and discarded
on Day 0. After 24 h (Day 1), 3 larvae were removed from each
container, weighed, and discarded. The remaining larvae were fed
with 1 mL of nutrient medium on Day 1, and then 2 mL on each of
Days 2 and 3. Late on Day 4, the containers were placed into larger
pots with a layer of sand at the base to serve as a medium for pu-
pation, and returned to the incubator. Pupae were recovered from
the sand on sieves on Day 9, and counted.
Each compound was examined at four or ﬁve serially diluted (5-
fold) concentrations. Each experiment consisted of a single
container at each concentration of HDAC inhibitor or insecticide,
alongside 4 control assays. Two separate experiments were per-
formed for each compound. The effect of the compounds on larval
development was deﬁned in two ways:
i) Larval weight gain in ﬁrst 24 h; the total weight gain of the 3
larvae sampled on Day 1 was expressed as a percentage of the
mean of the weight gain of the 3 larvae sampled from each of
the 4 control containers (weight gain was calculated by differ-
ence using weight on Day 1 and the mean weight of larvae on
Day 0);
ii) Pupation rate; the number of pupae in each drug-treated
container was expressed as a percentage of the mean number
of pupae in the 4 control containers.
The larval weight and pupation rate dose-response data were
analysed with GraphPad Prism® software using non-linear regres-
sion, with the ‘variable slope’ option selected, in order to calculate
IC50 values (with 95% Conﬁdence Intervals) representing the con-
centration of inhibitor required to reduce the larval weight gain or
pupation rate to 50% of that measured in control (no drug)
treatments.
2.3. Nuclear extract preparation
Nuclear extracts were prepared from blowﬂy eggs (0.5 g) using a
Nuclear Extraction kit (Millipore, USA) following the manufac-
turer's protocol with somemodiﬁcations. The chorionwas removed
by soaking for 80 s in a solution of bleach (2% v/v), followed by
centrifugation to sediment the eggs. The eggs were washed 3 times
in ice cold PBS. Complete Mini Protease Inhibitor (Roche, Basel
Table 1
HDAC inhibitors and insecticides used.
Drug group Compound Human HDACs Inhibited References Source
1) HDAC inhibitors
Hydroxamic acids Trichostatin Class I and II Yoshida et al., 1995 Selleckchem
CUDC-907 Class I and II; also class I PI3K Qian et al., 2012 Selleckchem
AL1179-3b Class I and II Kahnberg et al., 2006 synthesized
AR-42 Class I and II Lu et al., 2005; Tseng et al., 2015 ApexBio
Quisinostat Class I and II Arts et al., 2009 Selleckchem
PG50 HDAC6 Gupta et al., 2010 synthesized
Nexturastat A HDAC6 Bergman et al., 2012 ApexBio
AL1179-84 Class I and II Kahnberg et al., 2006 synthesized
Panobinostat Class I and II Atadja, 2009; Rajkumar and Kumar,
2016
ApexBio
Pracinostat (SB939) Class I and II Novotny-Diermayr et al., 2010 ApexBio
SBHA Class I and II Richon et al., 1998 ApexBio
AL-1179-85 Class I and II Kahnberg et al., 2006 synthesized
SAHA (Vorinostat) Class I and II Richon et al., 1998; Iwamoto et al., 2013 ApexBio
Givinostat Class I and II Leoni et al., 2005 ApexBio
M344 Class I and II Heltweg et al., 2004 ApexBio
Resminostat Class I and II Mandl-Weber et al., 2010 ApexBio
Belinostat Class I and II Plumb et al., 2003; Thompson, 2014 ApexBio
Naphthohydroxamic acid HDAC8 Krennhrubec et al., 2007 Sigma-Aldrich
Droxinostat Class I and II Wood et al., 2010 ApexBio
CAY10603 Class I and II Kozikowski et al., 2008 Santa Cruz
Biotech
VAHA (Valproic acid
hydroxamate)
Class I and II Fass et al., 2010 Santa Cruz
Biotech
MC-1568 Class IIa Mai et al., 2005 Selleckchem
ABHA Class I and II Andrews et al., 2000 synthesized
NW58 HDAC 1& 2 Wheatley et al., 2010 synthesized
Tubacin HDAC6 Butler et al., 2010 Selleckchem
HPOB HDAC6 Lee et al., 2013 ApexBio
BRD73954 HDAC6 and HDAC8 Olson et al., 2013 ApexBio
CUDC-101 Class I and II
EGFR (epidermal growth factor receptor)
HER2 (human epidermal growth factor receptor 2)
Lai et al., 2010 ApexBio
Rocilinostat HDAC6 Santo et al., 2012 Selleckchem
Tubastatin A HDAC6 Butler et al., 2010 ApexBio
PCI-34051 HDAC8 Balasubramanian et al., 2008 Santa Cruz
Biotech
Cyclic
depsipeptide
Romidepsin Class I Furumai et al., 2002; Barbarotta and
Hurley 2015
ApexBio
Benzamides Entinostat Class I Hu et al., 2003 ApexBio
Mocetinostat Class I Fournel et al., 2008 ApexBio
Thioester KD5170 Class I and II Hassig et al., 2008 ApexBio
Disulﬁde Psammaplin A Class I Baud et al., 2012; Kim et al., 2007 Santa Cruz
Biotech
Thiolate TCS HDAC620b HDAC6 Suzuki et al., 2006 ApexBio
Cyclic
tetrapeptide
Apicidin HDAC1; Anti-protozoan activity Jones et al., 2006; Darkin-Rattray et al.,
1996
ApexBio
Fatty acids Valproic acid Class I and II Phiel et al., 2001; Fass et al., 2010 Sigma-Aldrich
Pivanex (AN-9) Histone hyperacetylation Rabizadeh et al., 2007 Sigma-Aldrich
Sesquiterpene
lactone
parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz
Biotech
2) Commercial blowﬂy insecticides
Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown e Fluka
Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle
extensibility
Kotze and Reynolds, 1990 Chem Service
Benzoyl phenyl
urea
Diﬂubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service
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rupting them by handwith a plastic pestle. The disrupted eggswere
centrifuged at 250g for 1min at 4 C, and supernatant removed. The
egg cell pellet was washed with 1000 mL of ice cold PBS, resus-
pended by inversion, centrifuged at 1000g for 5 min at 4 C, and the
supernatant removed. This wash step was repeated a further 2
times. The cells were then disrupted by drawing 5 times through a
21 g needle ﬁtted to a 1mL syringe. The suspensionwas centrifuged
at 8000g for 20 min at 4 C, the supernatant removed and dis-
carded, and the pellet retained (nuclear portion). The nuclear pellet
was resuspended in 2/3 of the original cell pellet volume of ice coldnuclear extraction buffer (containing 0.5 mM DTT and protease
inhibitor cocktail, Millipore, Temecula). The solution was placed on
low speed roller for 1 h at 4 C, then centrifuged at 16000g for 5min
at 4 C, and the supernatant (the nuclear extract) transferred to a
new tube. The protein concentration was measured by the method
of Bradford (1976) using the Bio-Rad protein assay reagent, and
bovine serum albumin as a standard. The extract was then ali-
quoted into separate tubes, snap-frozen in liquid nitrogen, and
stored at 80 C.
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A ﬂuorometric assay kit (Sigma-Aldrich, USA) was used to
measure HDAC enzyme activity in blowﬂy nuclear extracts, as
described in the kit instructions, except that the volumes of all
reagents were reduced to give a total assay volume of 27.5 mL. Each
assay contained approximately 15 mg of nuclear extract protein.
HDAC activity was measured in the presence or absence of HDACi.
Control assays were also run in the presence of 1.25 mM trichostatin
in order to calculate the amount of ﬂuorescent product that was
derived from a trichostatin-inhibitable reaction, that is, the amount
of product derived from the action of HDAC enzymes alone. The
assay was performed using a series of at least 4 serially-diluted
working solutions of each HDACi. Duplicate assays were per-
formed at each HDACi concentration. The fold dilutions used to
generate each working solution series varied from 2efold to 10-
fold, and were set (based on initial dose-ﬁnding experiments) in
order to provide a dose response curve consisting of 4e6 data
points. The % inhibition of HDAC activity was calculated for each
concentration of HDACi added to the reaction. The enzyme assay
dose-response data were analysed with GraphPad Prism® software
using non-linear regression, with the ‘variable slope’ option
selected, in order to calculate IC50 values (with 95% Conﬁdence
Intervals) representing the concentration of inhibitor required to
reduce the HDAC activity of the nuclear extract by 50%.
2.5. Larval and enzyme assay comparisons
We performed a non-parametric (Spearman) correlation anal-
ysis in GraphPad Prism® in order to examine the relationship be-
tween the effects of HDACi in inhibiting blowﬂy larval development
and inhibiting nuclear extract HDAC enzyme activity. In addition, in
order to examine the relationship between the blowﬂy bioassay
data and the reported inhibitory effects of the HDACi against spe-
ciﬁc human HDAC enzymes, we performed a correlation analysis
using the bioassay data and IC50 values reported in the scientiﬁc
literature for the HDACi against human HDAC enzymes (see
Supplementary Table 1). While blowﬂies are known to possess
HDAC1, 3, 4, 6 and 11, (Kotze et al., 2015), the analysis was only
performed with human HDAC1, 3, 4 and 6 as insufﬁcient inhibition
data was available for an analysis of inhibitory effects on human
HDAC11. For the correlation analysis, we grouped HDAC 1 and 3
together as Class I HDAC enzymes, and HDAC4 and 6 together as
Class II HDAC enzymes.
3. Results
Forty HDACi compounds were investigated for inhibition of the
growth of blowﬂy larvae, with their activities reported in Table 2 as
inhibition of larval weight gain and pupation (mg/assay). For com-
parison, the toxicities of three commercial blowﬂy insecticides are
also reported in Table 2. The most potent inhibitor of blowﬂy larval
growth was the depsipeptide romidepsin, which was more potent,
or as potent as, the commercial insecticides: 10-fold more potent
than cyromazine, 2-fold more potent than diﬂubenzuron, and
equipotent with dicyclanil (Table 2, Figs. 1 and 2). The most potent
hydroxamic acids were trichostatin, CUDC-907, AL179-3b and AR-
42: approximately 10-fold less potent than cyromazine, and
approximately 50e100efold less potent than diﬂubenzuron and
dicyclanil. Also showing marked activity (IC50 < 100 mg/assay) were
the thioester compound KD5170, the disulﬁde compound Psam-
maplin A (which is a prodrug that forms a thiolate much like
romidepsin), and the cyclic tetrapeptide apicidin. Many of the
compounds, including 13 of the hydroxamic acids, the two fatty
acids (valproic acid and AN-9), and the single sesquiterpene lactone(parthenolide) showed little or no insecticidal activity
(IC50 > 1000 mg/assay).
Comparisons between the larval weight gain and pupation IC50
for the commercial insecticides showed that the two values were
within 2-fold of each other. For 7 of the 8 most active HDACi (larval
IC50 < 100 mg/assay, Fig. 2), the variation between the larval and
pupation IC50 values was also within a 2-fold range. The two values
were approximately equal for CUDC-907 and AR-42, while within
2-fold for trichostatin, AL1179-3b, romidepsin and KD5170. On the
other hand, the pupation IC50 for apicidinwas 6-fold higher than for
larval weight gain.
The HDACi were also investigated for inhibition of HDAC activity
in nuclear extracts from blowﬂy eggs (Table 3), with representative
dose-response curves shown in Fig. 3 (some of the compounds
shown in Tables 1 and 2 were not examined in nuclear extract as-
says as insufﬁcient material was available). As with the insecticidal
assays, romidepsin was the most potent inhibitor of HDAC activity.
This compound was approximately 600-fold more potent than the
second most-active compound, quisinostat, and about 1000-fold
more potent than trichostatin. The hydroxamic acids that were
the most active in the blowﬂy larval bioassay were among the most
potent enzyme inhibitors (IC50 0.016e0.212 mM for trichostatin,
CUDC-907 and AR-42). A number of hydroxamic acids that were
signiﬁcant HDAC enzyme inhibitors in the nuclear extracts
(IC50 < 0.3 mM) had low potency in the larval bioassay (e.g. pan-
obinostat, givinostat, belinostat: larval IC50 295, 477, and 740 mg/
assay, respectively). Among the other compounds highlighted
above for their insecticidal activity (from Fig. 2), all showed sig-
niﬁcant potency in inhibiting the HDAC enzyme activity of the
nuclear extract (all IC50 < 1 mM).
The relationship between larval bioassay IC50 and nuclear
extract HDAC inhibition IC50 is shown in Fig. 4 (Fig. 4A showswhole
data set, Fig. 4B shows data points with extract HDAC inhibition
IC50 < 2.0 mM only). Analysis of the whole data set (Fig. 4A),
revealed that the two assay parameters were signiﬁcantly corre-
lated (Spearman correlation coefﬁcients shown on Figure panels).
Despite this, some differences between the two measurements
were apparent, with larval weight IC50 values of 1000 (n ¼ 14)
corresponding to a range of nuclear extract activities from 0.032 mM
(CUDC-101) to > 100 mM (six compounds). Importantly, low larval
weight IC50 values (<100 mg/assay) did not occur alongside high
nuclear extract IC50. Fig. 4B illustrates this, with the most active
insecticidal compounds all being potent inhibitors of HDAC activity
in blowﬂy nuclear extracts (IC50 < 0.5 mM).
We also examined the relationship between published IC50
values for inhibition of human HDAC enzymes by the HDACi used in
this study with their activity in inhibiting blowﬂy larval develop-
ment. The analysis was restricted to just the human HDACs that
corresponded to the Class I and Class II HDAC enzymes present in
the blowﬂy, namely HDAC1 and 3 (Class I) and HDAC4 and 6 (Class
II). The published data on the inhibition of human HDAC11 (cor-
responding to the other HDAC present in the blowﬂy) was not
extensive enough with respect to the HDACi examined in the pre-
sent study (see Supplementary Table 1) to allow for a separate
analysis of this Class IV HDAC. The relationship between the blowﬂy
bioassay data for each HDACi and the reported enzyme inhibition
IC50 values against the Class I and II human HDAC enzymes are
shown in Fig. 5. The two parameters were signiﬁcantly correlated
for the Class I enzymes, but not for the Class II enzymes. However,
even though a signiﬁcant correlation existed for Class I enzymes
across thewhole data set, a number of compounds that were potent
inhibitors of the human Class I enzymes showed no insecticidal
activity (IC50 > 1000 mg/assay). Similarly, some potent human Class
II HDAC inhibitors showed no insecticidal activity.
Table 2
Effects of HDACi and commercial insecticides on the development of blowﬂy larvae.
Drug group Compound Blowﬂy bioassay
Weight gain in ﬁrst 24 h Pupation
IC50
(mg/assay)
95% CI IC50
(mg/assay)
95% CI
1) HDAC inhibitors
Hydroxamic acids Trichostatin 10.4 5.3e20.4 20.6 16.0e26.6
CUDC-907 12.2 6.1e24.5 13.8 7.5e25.5
AL1179-3b 13.9 7.3e26.2 20.0 14.6e27.3
AR-42 34.0 26.9e43.7 28.0 20.1e38.3
Quisinostat 100 39e260 274 149e501
PG50 101 26e388 >200
Nexturostat 137 68e279 >1000
AL1179-84 254 79e816 918 619-1360
Panobinostat 295 162e539 393 173e895
Pracinostat 302 110e834 >1000
SBHA 356 215e588 550 405e747
AL-1179-85 380 90-1607 863 746-1000
SAHA 434 247e763 >1000
Givinostat 477 157-1444 >1000
M344 490 294e804 890 632-1257
Resminostat 556 258-1200 >1000
Belinostat 740 426-1294 >1000
Naphthohydro. acid 778 335-1810 >1000
Droxinostat >1000 >1000
CAY10603 >1000 >1000
VAHA >1000 >1000
MC-1568 >1000 >1000
ABHA >1000 >1000
NW58 >1000 >1000
Tubacin >1000 >1000
HPOB >1000 >1000
BRD73954 >1000 >1000
CUDC-101 >1000 >1000
Rocilinostat >1000 >1000
Tubastatin A >1000 >1000
PCI-34051 >1000 >1000
Cyclic depsipeptide Romidepsin 0.124 0.103e0.149 0.196 0.102e0.374
Benzamides Entinostat 680 475e974 640 200-2056
Mocetinostat >1000 >1000
Thioester KD5170 40.6 20.6e79.9 75.3 52.6e107.9
Disulﬁde Psammaplin A 56.3 22.9e138.3 93.4 55.1e158.1
Thiolate TCS HDAC620b 284 171e470 >1000
Cyclic tetrapeptide Apicidin 83.3 51.5e134.5 489 218-1097
Fatty acids Valproic acid >1000 >1000
AN-9 >1000 >1000
Sesquiterpene lactone Parthenolide >1000 >1000
2) Commercial blowﬂy insecticides
Pyrimidine Dicyclanil 0.115 0.0160e0.829 0.0634 0.0519e0.0776
Diamino-triazine Cyromazine 1.27 0.673e2.40 1.54 0.600e3.96
Benzoyl phenyl urea Diﬂubenzuron 0.230 0.133e0.400 0.119 0.0941e0.151
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The present study has examined the ability of a number of
known HDACi to inhibit the growth and development of blowﬂy
larvae, and correlated this effect with their ability to inhibit the
HDAC activity of nuclear extracts prepared from blowﬂy eggs. There
was a signiﬁcant correlation, suggesting that their insecticidal ac-
tivity was likely due to the inhibition of blowﬂy HDAC enzymes.
Romidepsin was a very potent inhibitor of both blowﬂy larval
growth and blowﬂy HDAC activity, the potency being equivalent to
or greater than commercial blowﬂy insecticides. In addition, we
have shown that a number of other HDACi have signiﬁcant insec-
ticidal activity against blowﬂy larvae, including hydroxamic acids
(Trichostatin, CUDC-907, AL1179-3b, AR-42), a thioester (KD5170), a
disulphide (Psammaplin A) and a cyclic tetrapeptide with a zinc-
binding ketone (Apicidin).
While these HDACi validate the concept of a potentially valuable
new target for insecticides, we are not advocating the use of theparticular compounds reported herein as commercial insecticides.
They would be too expensive to be economically viable for any
livestock or agronomic production setting. Moreover, most of the
more potent HDACi described are also potent inhibitors of human
HDACi (IC50 nM - mM) and might prove cytotoxic in sheep and
unacceptable in terms of human consumption of sheepmeat.
Hence, while our demonstration of the potent insecticidal activity
of a number of HDACi helps to prove the concept that HDACimay be
effective insecticides, issues associated with cost of production and
target pest selectivity need to be solved next.
Romidepsin is a prodrug that is ﬁrst activated by reduction of its
disulﬁde to the free thiol that can then bind to the catalytic Zn2þ in
HDAC enzymes. Thiols or thiolates have a much lower binding af-
ﬁnity for Zn2þ than hydroxamic acids. The higher potency of
romidepsin involves either a highly complementary ﬁt of the con-
formationally constrained cyclic depsipeptide component of
romidepsinwith the enzyme, or higher metabolic stability than the
hydroxamates. Apicidin is another compound with signiﬁcant
Fig. 1. Effects of HDACi (coloured solid symbols and lines; named in key) and com-
mercial insecticides (open symbols dashed lines; cyromazine ◊, diﬂubenzuron ,,
dicyclanilB) on the growth of blowﬂy larvae. Each data point represents mean ± SE,
n ¼ 2 assays at each compound concentration. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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peptide component that adds afﬁnity to the relatively weak inter-
action between its ketone component and zinc. Interestingly, Engel
et al. (2015) found that romidepsin inhibited the growth of asexual
stage Plasmodium falciparum (IC50 0.1 mM), the bloodstream form
Trypanosoma brucei parasites (IC50 0.035 mM), and was a potent
inhibitor of HDAC enzyme activity in P. falciparum nuclear extracts
(IC50 0.9 nM).
In contrast, most hydroxamic acid based inhibitors derive their
afﬁnity from zinc chelation which sometimes compensates for a
suboptimal ﬁt between the remaining features of the inhibitor and
the enzyme active site. The 31 hydroxamic acids examined here
have considerable structural diversity and are mostly potent in-
hibitors of human HDACs. They show quite a range of inhibitory
potencies against blowﬂy larval growth over two log units (Table 2).
Most of the hydroxamate-based inhibitors were derived from 4-
aminopyrimidine or 4-aminobenzene hydroxamic acids, which
confer an extended linear shape to the fragment projecting towards
Zn2þ in the enzyme. Trichostatin has a similarly rigid linear struc-
ture due to its highly conjugated oleﬁn components. Other active
inhibitors with a linear structure due to an aromatic group in
conjugationwith a double bond and hydroxamate are the cinnamic
acid hydroxamates, panobinostat & pracinostat. The potent sub-
eroylhydroxamates (AL1179-3b & PG50) have a more ﬂexible linear
zinc-binding extension like the similarly ﬂexible but simpler parent
compound SAHA, but exhibit superior activity attributed to their
branched capping group that likely makes multiple interactions
with the enzyme. PG50 was developed as a selective inhibitor of
human HDAC6 (Gupta et al., 2010), however it seems to be a class I
HDACi in the blowﬂy possibly suggesting its capping groups are too
small to inﬂuence selectivity as the other hydroxamate inhibitors
known to speciﬁcally inhibit human HDAC6 (tubacin & tubastatin
A) were inactive in the blowﬂy bioassay. The reasons why other
hydroxamates were inactive is not clear, but they do show how
selectivity between highly homologous enzymes can be achieved,
in this case away from blowﬂy and towards human. In principle this
trend might be reversed with new compounds. Clues derived from
the capping cyclic peptide groups away from the zinc-binding
moieties of romidepsin and apicidin may steer the developmentof new compounds with greater potency and selectivity for the
target enzyme to make better and safer insecticides.
Two aspects of the time course of insecticidal effects are
important for blowﬂy control. Firstly, effective insecticides must
kill, or inhibit the growth of early stage larvae before they can
damage the host. Secondly, where the initial effects are inhibitory
rather than lethal, they must persist over at least several days and
then kill the larva to prevent it recovering and developing to
damage the host. A comparison of the two bioassay IC50 values is
informative with respect to these time course considerations. The
commercial insecticides show a pupation IC50 that is similar
(within two fold) to the 24 h weight gain IC50, consistent with the
larvae not recovering from an initial growth inhibition phase. This
was also observed for seven of the eight HDACi highlighted in Fig. 2.
Apicidin on the other hand showed a pupation IC50 value almost 6-
fold greater than the weight gain IC50, indicating some recovery of
larvae after the initial inhibitory effects on growth.
A number of compounds showed potent inhibition of the nu-
clear extract HDAC activity, but only low or no activity in the larval
bioassay (for example: nuclear enzyme assay CAY10603 IC50
0.165 mM, CUDC-101 0.0317 mM vs larval bioassay IC50 > 1000 mg/
assay). This is likely due to poor uptake or low stability of the
compounds in the larval assay. There are likely to be differences
between the various compounds examined in terms of uptake
across the larval cuticle (trans-cuticular uptake) and across the
intestinal membranes (following ingestion), as well as access to the
cellular target following uptake. Some of the compounds are likely
to be metabolised to a greater degree than others by the blowﬂy
xenobiotic-detoxiﬁcation systems, which include esterases
(Campbell et al., 1997), cytochromes P450 (Kotze, 1993) and
glutathione transferases (Kotze and Rose, 1987).
Potency against human class I HDAC enzymes generally corre-
lated with insecticidal activity, but some potent inhibitors of hu-
man Class I HDAC (IC50 < 0.10 mM) showed no insecticidal activity.
This may be due to factors associated with uptake and stability of
the compounds in the bioassay, as well as differences in the
intrinsic level of interaction of the compounds with the human
enzymes compared to the equivalent blowﬂy HDAC enzymes. Kotze
et al. (2015) described some differences in the amino acid residues
between the human and blowﬂy Class I HDACs, with catalytic
domain amino acids showing 86% and 73% identities between hu-
man and blowﬂy HDAC1 and 3, respectively. The relationship be-
tween inhibitory effects of HDACi on human Class II HDACs and
their insecticidal activity was poor, with no signiﬁcant correlation
between the two parameters. The catalytic domain amino acids
differ to a much greater extent between the human Class II HDACs
and their blowﬂy equivalents compared to the Class I comparisons,
with % identities of 61%, 47% and 50% for HDAC 4 and the two
catalytic domains of HDAC6, respectively, between the human and
blowﬂy (Kotze et al., 2015). Hence, HDACi of human and blowﬂy
Class II enzymes may show a lower level of relatedness than among
inhibitors of Class I enzymes from the two species. The lack of
correlation for Class II HDACs may be favourable for potential
identiﬁcation of more insect-speciﬁc HDACi that interact specif-
ically with the blowﬂy Class II enzymes, while showing less inhi-
bition of the human Class II enzymes. However, more information
on the different roles played by the blowﬂy Class I and II HDAC
enzymes is required before a preferred target HDAC Class or indi-
vidual enzyme can be determined. Foglietti et al. (2006) found that
RNAi emediated silencing of Drosophila HDACs 1 and 3 resulted in
inhibitory effects on growth curves for Drosophila Schneider (S2)
cell lines, whereas silencing of HDACs 4, 6 and 11 did not inhibit cell
growth, suggesting more important roles for the two Class I en-
zymes in cell viability. Du et al. (2010) reported that Drosophila
HDAC6 loss-of-function mutant ﬂies were viable and fertile,
Fig. 2. Structures of HDACi with the most potent inhibition of blowﬂy larval development (larval weight gain IC50 < 100 mg/assay).
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Table 3
Effects of HDACi on HDAC activity of nuclear extracts from blowﬂy eggs.
Drug group Compound Nuclear extract assay
IC50
(mM)
95% CI
Hydroxamic acids Trichostatin 0.016 0.011e0.022
CUDC-907 0.11 0.08e0.17
AR-42 0.21 0.18e0.26
Quisinostat 0.009 0.003e0.022
Nexturostat 5.1 3.2e8.3
Panobinostat 0.017 0.012e0.025
Pracinostat 0.69 0.58e0.82
SBHA 9.9 6.5e15.2
SAHA 0.39 0.30e0.50
Givinostat 0.19 0.15e0.24
M344 0.58 0.41e0.81
Resminostat 1.71 1.27e2.30
Belinostat 0.27 0.19e0.36
Naphthohydro. acid 83 54e128
Droxinostat 49 40e59
CAY10603 0.17 0.10e0.27
VAHA >100
ABHA 2.6 1.5e4.6
Tubacin 26 18e37
HPOB 17 13e20
BRD73954 >100
CUDC-101 0.032 0.014e0.070
Rocilinostat 2.0 1.6e2.4
Tubastatin A 71 37e133
PCI-34051 >100
Cyclic depsipeptide Romidepsin 0.000014 0.00001e0.00002
Benzamides Entinostat 15 5e46
Mocetinostat >100
Thioester KD5170 0.41 0.32e0.50
Disulﬁde Psammaplin A 0.015 0.007e0.032
Thiolate TCS HDAC620b >100
Cyclic tetrapeptide Apicidin 0.72 0.45e1.14
Fatty acid Valproic acid >100
Sesquiterpene lactone Parthenolide >100
Fig. 3. Effects of HDACi (named in key) on HDAC activity of nuclear extracts prepared
from blowﬂy eggs. Each data point represents mean ± SE, n ¼ 2 assays at each com-
pound concentration.
Fig. 4. Relationship for HDACi in inhibiting blowﬂy larval development (larval weight
gain IC50) versus blowﬂy HDAC activity (nuclear extract IC50). A: whole data set
(n ¼ 34), with Spearman correlation coefﬁcient and P value; data points at 100 mM for
nuclear extract inhibition and/or 1000 mg/assay for larval weight were measured
as > 100 and > 1000, respectively. B: Only the most potent inhibitors of HDAC activity
(IC50 < 2.0 mM, n ¼ 16), with Spearman correlation coefﬁcient and P value; circled data
points are for romidepsin, TSA, CUDC-907, AR 42, KD5170 and Psammaplin A.
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opment of this ﬂy species.
In conclusion, the present study shows that HDACi from various
chemical groups can substantially inhibit the development ofblowﬂy larvae. In particular, romidepsin was at least equipotent
with the major commercial blowﬂy insecticides, supporting the
concept of inhibiting blowﬂy HDAC enzymes to produce new in-
secticides for preventing infection by sheep blowﬂy, and to
potentially control other insects. There is a great deal of interest
currently in developing HDAC inhibitors for use in chemotherapy
against other human parasitic disease e malaria, toxoplasmosis,
trypanosmiasis, schistosomiasis and leishmaniasis (Andrews et al.,
2012a,b, 2014; Kelly et al., 2012; Hansen et al., 2014; Engel et al.,
2015; Marek et al., 2015). A focus of these studies is the identiﬁ-
cation of HDACi that show selectivity for the parasite HDAC en-
zymes over the human enzymes. Similarly, further work on
developing HDAC inhibitors as potent insecticides could focus on
identifying insect-speciﬁc inhibitors, but at the very least should
focus on producing HDACi that are cheap to manufacture and
market as prospective insecticides.
Fig. 5. Relationship for HDACi in inhibiting larval development (larval weight gain
IC50) versus human Class I enzymes (HDAC1 B, HDAC3 -) (A) (n ¼ 45), and human
Class II enzymes (HDAC4 C, and HDAC6 D) (B) (n ¼ 37). Spearman correlation co-
efﬁcients and P values shown. Data points at 20 mM for human enzyme inhibition and/
or 1000 mg/assay for larval weight were measured as > 20 and > 1000, respectively.
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